[COVID-19 effect on mental health and sleep disorders]

To study the prevalence of anxiety-depressive disorders and sleep disorders in their structure among patients hospitalized in connection with COVID-19, as well as to develop differentiated recommendations for their therapy in patients with new coronavirus infection.

In this publication, the authors present preliminary results of their own observations of psychoemotional disorders and sleep disorders in their structure in patients with a new coronavirus infection. We analyzed the data of 119 patients (aged 47 to 69 years, male and female), conducted a detailed interview, including using telemedicine technologies, and assessed the scales: The hospital Anxiety and Depression Scale (HADS), subjective the asthenia rating scale (MFI-20, Multidimensional Fatigue Inventory) and the Pittsburgh Sleep Quality Index (PSQI) questionnaire.

According to the results of the HADS questionnaire, clinically pronounced anxiety-depressive symptoms were observed in 33 (28%) patients of 119 hospitalized in connection with the diagnosis of COVID-19. Of them, only clinically significant anxiety was recorded in 11% of cases (n=13), in 5 (4%) patients - clinically significant depression, an increase in both subscales of anxiety and depression - in 13% (n=15). An increase in the MFI-20 scale (more than 20 points) was found in 87 (73%) patients, sleep disorders in accordance with the PSQI questionnaire was recorded in 32 (27%) patients.

According to the results of the study, it was noted that in most patients with COVID-19, along with a depressive symptom complex, anxiety and hypochondriacal disorders, an asthenic symptom complex, sleep disturbances with difficulty falling asleep, and dissatisfaction with the quality of sleep are recorded. Differentiated recommendations for the treatment of the studied conditions have been developed, taking into account the side effects of the prescribed drugs, drug interactions and the characteristics of the somatic status of patients. The choice of the drug should be based on the severity of the violations identified.